Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells

AIM: Inhibition of heat shock protein (Hsp90) has been proven to be effective in overriding primary and acquired resistance of kinase inhibitors. In this study, we investigated the role of FS-108, a newly developed Hsp90 inhibitor, to overcome gefitinib resistance in EGFR mutant non-small cell lung...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Acta Pharmacol Sin
Huvudupphovsmän: Wang, Yue-qin, Shen, Ai-jun, Sun, Jing-ya, Wang, Xin, Liu, Hong-chun, Zhang, Min-min, Chen, Dan-qi, Xiong, Bing, Shen, Jing-kang, Geng, Mei-yu, Zheng, Min, Ding, Jian
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group 2016
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5260832/
https://ncbi.nlm.nih.gov/pubmed/27616574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aps.2016.85
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk